Komori
Share Issuance and Disposal4893Noile-Immune Biotech Inc.Pharmaceuticals

Notice of Completion of Payment for New Shares Issued as Restricted Stock-Based Compensation

Payment for 97,353 new shares issued as restricted stock compensation, as resolved on 15 April 2026, was completed on 14 May 2026.

Worth reading
45Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
97353
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares as restricted stock compensation

Who receives how much97,353Shares

97,353 shares (new shares)

Directors of the Company (excluding outside directors)3 / 83,853 shares
The Company's outside directors2 / 13,500 shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

¥150 per share
Total issue value

¥14,602,950

Categories and Number of Persons Covered
Category Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of allocated shares 83,853 shares, Category The Company's outside directors / Number of Employees 2 / Number of allocated shares 13,500 shares
Payment date
14 May 2026
Most recent equity financing
Issuance of new shares as restricted stock compensation pursuant to a resolution of the Board of Directors meeting held on 15 April 2026 (detailed amount not disclosed in this document)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares as restricted stock compensation
Number of shares to be issued or disposed of97,353 shares (new shares)
Issue price and disposal price¥150 per share
Total issue value¥14,602,950
Payment date14 May 2026
Intended allotteeCategory Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of Shares 83,853 shares, Category The Company's outside directors / Number of Employees 2 / Number of Shares 13,500 shares
Categories and Number of Persons CoveredCategory Directors of the Company (excluding outside directors) / Number of Employees 3 / Number of allocated shares 83,853 shares, Category The Company's outside directors / Number of Employees 2 / Number of allocated shares 13,500 shares
Most recent equity financingIssuance of new shares as restricted stock compensation pursuant to a resolution of the Board of Directors meeting held on 15 April 2026 (detailed amount not disclosed in this document)
Items this document does not state (20)
Amount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the shares were issued as restricted stock compensation.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for New Shares Issued as Restricted Stock-Based Compensation | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori